Since 2000, the Nippon Chemiphar Group has developed business under a management strategy focused on three principal goals: establishing a strong presence in the generics business; applying alkalizer-related expertise multilaterally; and pursuing drug discovery and development.

We enhanced this strategy in 2015, by adding one goal: Plus 1. The step represents our overseas market expansion, centered on Asia, that will allow us to improve results even in areas where we already have logged achievements.

By simultaneously pursuing the above initiatives, each of which has a different timeline, we will target sustainable growth through our distinctive business model and by delivering our unique value to all our stakeholders.

Over the past three-plus years, efforts associated with new drugs have allowed us to make steady progress. This includes the licensing agreements we have concluded for anticancer drugs DFP-17729 and DFP-14323; a collaborative research and development agreement; an option agreement and commencement of phase 1 trials for NC-2800, an internally developed antidepressant and antianxiety agent candidate; as well as the licensing out of NC-2500.

In addition, we have generated consistent advances through innovation-related initiatives, which include the launch of our DropScreen allergy diagnostic product. In the category of generic drugs, we have increased the strength of our quality initiatives and are also solidifying our business foundation by implementing Groupwide structural reforms that enhance efficiency throughout our supply chain. At the same time, we have reinforced our production system, which comprises an extensive network of facilities and many employees.

We look forward to the continued support of all our stakeholders in these endeavors.

Kazushiro Yamaguchi
President&CEO